DOJ Sues Healthpoint Over Zenaderm Marketing
The U.S. Department of Justice on Thursday accused Healthpoint Ltd. of falsely marketing the bedsore ointment Xenaderm as a prescription drug qualifying for Medicare and Medicaid reimbursement, causing the agencies to...To view the full article, register now.
Already a subscriber? Click here to view full article